EF001 免責聲明 第 1 頁 共 2 頁 v 1.1.1 EF001 其他信息 其他信息 不適用 發行人董事 於本公告日期，執行董事為葉小平博士、曹曉春女士、吳灝先生及聞增玉先生；本公司獨立非執行董事為廖啟宇先生、袁華 剛先生及劉毓文女士。 第 2 頁 共 2 頁 v 1.1.1 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 杭州泰格醫藥科技股份有限公司 | | | 股份代號 | 03347 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年12月31日止年度之末期股息 | | 公告日期 | 2026年3月30日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣 ...

Core Viewpoint - The company, Tigermed (03347.HK), reported a revenue increase of 3.5% year-on-year for the fiscal year 2025, with significant profit growth driven by the recovery of the domestic biopharmaceutical industry and increased demand for clinical research outsourcing services [1][2]. Group 1: Financial Performance - Revenue rose from RMB 6.603 billion to RMB 6.833 billion, reflecting a year-on-year growth of 3.5% [1] - Profit increased by 79.8% to RMB 0.805 billion during the reporting period [1] - Profit attributable to shareholders surged by 119.2% to RMB 0.888 billion [1] - Basic earnings per share reached RMB 1.04, with a proposed final dividend of RMB 1.26 per 10 shares [1] Group 2: Industry Trends - The domestic biopharmaceutical industry is recovering, contributing to sustained demand for clinical research outsourcing services [1] - The clinical research outsourcing industry is undergoing further consolidation, leading to improved competition [1] - The company is focusing on developing business opportunities from both domestic pharmaceutical companies and large multinational pharmaceutical firms [1] Group 3: Order Growth - New orders increased significantly, with net new orders amounting to RMB 10.2 billion, representing a year-on-year growth of 20.6% [2] - The average price of new orders has stabilized and is expected to return to a growth trend in 2026 [2] - The total amount of contracts to be executed reached RMB 18.2 billion, marking a year-on-year increase of 15.4% [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 除建議修訂 公司章程 外，公 司 章 程 的 其 他 條 款 保 持 不 變。建 議 修 訂 公 司 章 程 以 中 文 編 製，中 英 文 版 如 有 歧 義，概 以 中 文 版 為 準。 建 議 修 訂 公 司 章 程 須 待 本 公 司 股 東（「股 東」）於 本 公 司 股 東 會（「股 東 會」） 上 通 過 特 別 決 議 案 批 准。董 事 會 同 意 提 請 股 東 會授權董事會並由董事會 轉 授 權 本 公 司 管 理 層 辦 理 該 等 章 程 修 訂 所 涉 及 的 相 關 監 管 機 構 審 批、備 案 手 續，並 根 據 監 管 機 構 的 意 見 對 公 司 章 程 修 訂 內 容 進 行 文 字 等 調 整。 一般事項 杭州泰格醫 ...

格隆汇3月30日丨泰格医药(03347.HK)发布2025年度业绩。报告期间，收入由同期的人民币66.03亿元增 至人民币68.33亿元，同比增长3.5%。期内利润增加79.8%至报告期间的人民币8.05亿元。公司拥有人应 占利润增加119.2%至报告期间的人民币8.88亿元。基本每股盈利1.04元，董事会建议宣派截至2025年12 月31日止年度的末期股息每10股人民币1.26元(含税)。 2025年，随着国内生物医药行业的恢复，以及中国创新药研发产业链进一步融入全球版图，临床研究外 包服务需求延续了复苏态势。同时，2025年临床研究外包行业进一步整合，行业竞争趋於良性。公司商 务发展(BD)部门及全体员工一方面继续深耕国内优质客户，持续开发临床研发及相关业务订单，尤其 是来自国内药企和优质生物科技公司的订单；另一方面也积极开拓来自大型跨国药企的业务机遇。 报告期内，新订单按年增长较2024年有所加快，净新增订单（新签订单剔除取消订单後）金额为人民币 102亿元，同比增长20.6%。2025年，新订单的平均单价已经企稳，并有望在2026年重回增长态势。截 至报告期末，待执行合同金额达人民币182亿元，同比增 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：3347） 截 至2025年12月31日止年度之 年度業績公告 財務摘要 | | | 截 至12月31日止年度 | | | --- | --- | --- | --- | | | 2025年 | 2024年 | 變 動(2) | | | 人民幣百萬元 | 人民幣百萬元 | | | 經營業績 | | | | | 收 入 | 6,832.8 | 6,603.1 | 3.5% | | 毛 利 | 1,873.2 | 2,242.0 | (16.4)% | | 本公司擁有人應佔淨利潤 | 887.9 | 405.1 | 119.2% | | ...

Group 1 - Schroders PLC increased its stake in Tiger Medical (300347) by acquiring 387,200 shares at a price of HKD 37.5304 per share, totaling approximately HKD 14.53 million [1] - After the acquisition, Schroders PLC's total shareholding in Tiger Medical reached 6.3153 million shares, representing a holding percentage of 5.13% [1]

Group 1 - Schroders PLC increased its stake in Tiger Medical (03347.HK) by acquiring 387,200 shares at an average price of HKD 37.5304 per share, totaling approximately HKD 14.53 million [1] - Following this acquisition, Schroders PLC's total shareholding rose to 6.3153 million shares, increasing its ownership percentage from 4.81% to 5.13% [1]

智通财经APP获悉，香港联交所最新资料显示，3月24日，Schroders PLC增持泰格医药(03347)38.72万 股，每股作价37.5304港元，总金额约为1453.18万港元。增持后最新持股数目为631.53万股，最新持股 比例为5.13%。 ...

Company Overview - Tiger Med is a clinical research service provider based in Hangzhou, China, established on December 15, 2004, and listed on August 17, 2012. The company specializes in providing professional clinical research services for pharmaceutical and health-related products, covering phases I to IV clinical trials, data management, regulatory submissions, and various medical services [1][7]. Stock Performance - On March 27, Tiger Med's stock rose by 5%, reaching a price of 53.32 CNY per share, with a trading volume of 696 million CNY and a turnover rate of 2.35%. The total market capitalization is 45.91 billion CNY. The stock has experienced a cumulative increase of 6.82% over the past three days [1][7]. Shareholder Insights - E Fund's ChiNext ETF (159915) is among the top ten shareholders of Tiger Med, having reduced its holdings by 1.88 million shares in the third quarter, now holding 11.26 million shares, which represents 1.63% of the circulating shares. The estimated floating profit today is approximately 28.60 million CNY, with a total floating profit of 36.48 million CNY over the past three days [2][8]. Fund Performance - E Fund's ChiNext ETF (159915) has a total asset size of 100.45 billion CNY, with a year-to-date return of 2.38%, ranking 1280 out of 5563 in its category. Over the past year, it has achieved a return of 55.52%, ranking 386 out of 4429, and since inception, it has returned 274.08% [2][8]. Fund Holdings - Six funds under E Fund have significant holdings in Tiger Med, totaling 2.56 million shares. Based on the previous day's closing price of 50.78 CNY, the estimated floating profit today is around 650,660 CNY, with a total floating profit of 829,980 CNY over the past three days [4][10]. Fund Manager Profiles - The fund managers of E Fund's ChiNext ETF (159915) are Cheng Xi and Liu Shurong. Cheng has been in the position for 9 years and 327 days, managing assets totaling 252.07 billion CNY, with the best return during his tenure being 131.04%. Liu has been managing 127.68 billion CNY for 8 years and 255 days, achieving a best return of 194.12% [3][9].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a cumulative increase of 6.82% over the past three days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I-IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Fund Holdings - Two funds under Yuanxin Yongfeng have heavily invested in Tiger Med, holding a total of 293,400 shares. Based on the previous closing price of 50.78 CNY, the current stock price of 53.32 CNY results in a daily floating profit of 745,200 CNY, with a total floating profit of 950,600 CNY over the past three days [2][8]. - Yuanxin Yongfeng Multi-Strategy Fund (004148) holds 185,900 shares, representing 3.18% of the fund's net value, while Yuanxin Yongfeng Consumption Upgrade Fund (004934) holds 107,500 shares, accounting for 3.3% of the fund's net value [3][7].